PI3K and mTOR pathway and molecular targeted agents

Kazuto Nishio, Kazuko Sakai, Yosuke Togashi

Research output: Contribution to journalReview articlepeer-review


Molecular alteration of PI3K and mTOR pathways is frequently detected in various types of cancers. PIK3CA mutations are the predictive markers for anti-EGFR antibodies, trastuzumab, and lapatinib. The p110 isoform selective PI3K inhibitors has been developed in the clinical settings to reduced off-target induced adverse events. Feedback loop for PI3K signal leads the resistance to PI3K inhibitors. Dual PI3K/mTOR inhibitors and mutation selective PI3K inhibitors are under evaluation to circumvent the resistance.

Original languageEnglish
Pages (from-to)1315-1322
Number of pages8
JournalNihon rinsho. Japanese journal of clinical medicine
Issue number8
Publication statusPublished - Aug 1 2015

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'PI3K and mTOR pathway and molecular targeted agents'. Together they form a unique fingerprint.

Cite this